Drug Interactions between lisinopril and losartan
This report displays the potential drug interactions for the following 2 drugs:
- lisinopril
- losartan
Interactions between your drugs
lisinopril losartan
Applies to: lisinopril and losartan
GENERALLY AVOID: Coadministration of angiotensin converting enzyme inhibitors (ACEIs) with angiotensin II receptor blockers (ARBs) may increase the risk of hyperkalemia, severe hypotension, and renal failure due to additive or synergistic effects on the renin-angiotensin system, particularly in patients with diabetes and/or renal impairment. A multicenter double-blind, randomized, controlled study evaluating the efficacy of combination-therapy with losartan (an ARB) and lisinopril (an ACEI) in slowing the progression of proteinuric diabetic nephropathy was stopped early on account of safety concerns due to increased rates of serious adverse events in the combination-therapy treatment group (hyperkalemia and acute kidney injury). Hyperkalemia occurred in 9.9% of patients in the combination-therapy group compared to 4.4% in the monotherapy group, and acute kidney injury events occurred in 18% of the combination-group compared to 11% in the monotherapy group.
MANAGEMENT: Coadministration of angiotensin converting enzyme inhibitors (ACEIs) with angiotensin II receptor blockers (ARBs) should generally be avoided, especially in patients with diabetic nephropathy and/or moderate to severe renal impairment (GFR <60 mL/min/1.73 m2). Some authorities consider this combination contraindicated in such patients. However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored particularly in the elderly, patients with worsening heart failure, or those at risk for dehydration. Additionally, potassium supplementation should generally be avoided unless potassium levels are closely monitored. Patients and their caregivers should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia (e.g., weakness, tingling of the extremities, irregular heartbeat) and/or acute kidney injury (e.g., reduced urine output, lower extremity edema). Individual product labeling should be consulted for further guidance.
References (37)
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
- (2001) "Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Micardis (telmisartan)." Boehringer-Ingelheim
- Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D (2002) "Dual renin-angiotensin system blockade at optimal doses for proteinuria." Kidney Int, 62, p. 1020-5
- Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH (2003) "Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy." Kidney Int, 63, p. 1874-80
- Rossing K, Jacobsen P, Pietraszek L, Parving HH (2003) "Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial." Diabetes Care, 26, p. 2268-74
- Jacobsen P, Andersen S, Jensen BR, Parving HH (2003) "Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy." J Am Soc Nephrol, 14, p. 992-9
- McMurray JJ, Ostergren J, Swedberg K, et al. (2003) "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial." Lancet, 362, p. 767-71
- Pfeffer MA, McMurray JJ, Velazquez EJ, et al. (2003) "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both." N Engl J Med, 349, p. 1893-1906
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- ONTARGET Investigators, Yusuf S, Teo KK, et al. (2008) "Telmisartan, ramipril, or both in patients at high risk for vascular events." N Engl J Med, 358, p. 1547-59
- Mann JF, Schmieder RE, McQueen M, et al. (2008) "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial." Lancet, 372, p. 547-53
- Guthrie RM (2009) "Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary." Postgrad Med, 121, p. 202-4
- National Kidney Foundation (2012) "KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update." Am J Kidney Dis, 60, p. 850-86
- EMA. European Medicines Agency (2014) PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys
- MHRA. Medicines and Healthcare Regulatory Agency (2014) Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905
- (2021) "Product Information. Irbesartan (irbesartan)." Alembic Pharmaceuticals
- (2021) "Product Information. Aprovel (irbesartan)." Sanofi
- (2021) "Product Information. Valsartan (valsartan)." Alembic Pharmaceuticals
- (2023) "Product Information. Auro-Valsartan (valsartan)." Auro Pharma Inc
- (2023) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals UK Ltd
- (2020) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals Pty Ltd
- (2023) "Product Information. Telmisartan (telmisartan)." Alembic Pharmaceuticals
- (2023) "Product Information. Ach-Telmisartan (telmisartan)." Accord Healthcare Inc
- (2023) "Product Information. Micardis (telmisartan)." Boehringer Ingelheim Ltd
- (2022) "Product Information. Micardis (telmisartan)." Boehringer Ingelheim Pty Ltd
- (2022) "Product Information. Olmesartan Medoxomil (olmesartan)." ASCEND LABORATORIES S.P.A.
- (2022) "Product Information. Olmesartan Medoxomil (olmesartan)." Thornton & Ross Ltd
- (2022) "Product Information. IXIA (olmesartán)." MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG, S.A.
- (2024) "Product Information. Losartan Potassium (losartan)." Strides Pharma Inc.
- (2023) "Product Information. Auro-Losartan (losartan)." Auro Pharma Inc
- (2022) "Product Information. Cozaar (losartan)." Organon Pharma (UK) Ltd
- (2022) "Product Information. Eprosartan (eprosartan)." Amarox Ltd
- (2021) "Product Information. Candesartan Cilexetil (candesartan)." Alembic Pharmaceuticals
- (2022) "Product Information. Amias (candesartan)." Neon Healthcare Ltd
- (2022) "Product Information. Edarbi (azilsartan)." Takeda UK Ltd
- Fried L, Emanuele N, Zhang J, brophy m, Conner TA, Duckworth W, et al. (2024) Combined angiotensin inhibition for the treatment of diabetic nephropathy https://www.nejm.org/doi/10.1056/NEJMoa1303154?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov#f02
Drug and food interactions
lisinopril food
Applies to: lisinopril
GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.
MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.
References (3)
- (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
- Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
- Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20
losartan food
Applies to: losartan
GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.
MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.
MONITOR: Grapefruit juice may modestly decrease and delay the conversion of losartan to its active metabolite, E3174. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The clinical significance is unknown. Moreover, pharmacokinetic alterations associated with interactions involving grapefruit juice are often subject to a high degree of interpatient variability.
MANAGEMENT: Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan. Grapefruits and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact.
References (3)
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E (2001) "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit, 23, p. 369-73
- Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20
lisinopril food
Applies to: lisinopril
MONITOR: Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.
MANAGEMENT: Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.
References (10)
- Sternbach H (1991) "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol, 11, p. 390-1
- Shook TL, Kirshenbaum JM, Hundley RF, Shorey JM, Lamas GA (1984) "Ethanol intoxication complicating intravenous nitroglycerin therapy." Ann Intern Med, 101, p. 498-9
- Feder R (1991) "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry, 52, p. 139
- Ellison JM, Milofsky JE, Ely E (1990) "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry, 51, p. 385-6
- Rodriguez de la Torre B, Dreher J, Malevany I, et al. (2001) "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit, 23, p. 435-40
- Cerner Multum, Inc. "Australian Product Information."
- Pacher P, Kecskemeti V (2004) "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des, 10, p. 2463-75
- Andrews C, Pinner G (1998) "Postural hypotension induced by paroxetine." BMJ, 316, p. 595
- (2023) "Product Information. Buprenorphine (buprenorphine)." G.L. Pharma UK Ltd
- (2023) "Product Information. Temgesic (buprenorphine)." Reckitt Benckiser Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.